"Peak" gathered in Qiantang!High -quality development of the biomedical industry

On June 30, the 2022 China (Zhejiang) Free Trade Zone Life and Health Industry Promotion Conference and the 6th International Biomedical (Hangzhou) Innovation Summit opened in Qiantang District.

Under the collection, is the medical field facing challenges or new opportunities? What is the development trend of cells and gene therapy industries and future development? How will the investment and financing hotspots and trends of investment in the pharmaceutical industry float?

At the meeting, the institutional dividend and policy integration advantages of the Zhejiang Free Trade Zone, and how to promote the high -quality development of the entire industry chain of the biomedicine, experts from well -known pharmaceutical companies at home and abroad, and investment and financing industries gathered together to the development of the biomedical industry Concern and suggestions.

Zhejiang Free Trade Zone

The Zhejiang Free Trade Zone was officially listed on April 1, 2017. On August 30, 2020, the "expanded area upgrade" was achieved to form a development pattern of "one district, four pieces". Among them, the nation's first reached 113 items, and 31 items were replicated to the whole country.

In the past five years, Zhejiang Pilot Zone has continued to deepen institutional innovation, reform integration, and project implementation, which has become a leading demonstration zone that serves a major strategy of the country and promotes high -quality economic development.

The summit interpreted the "Promoting High-quality Development Action Plan for the Biomedical Industry (2022-2024)" and released the "Hangzhou Pharmaceutical Port Biomedical Industry Innovation Development Plan" on the spot.

As a new industrial platform for Zhejiang Province, Hangzhou Pharmaceutical Port is becoming the core area of ​​the province's development of the biomedical industry. Data is the best evidence. In 2021, Hangzhou Pharmaceutical Port Biomedical Enterprise achieved revenue of 45 billion yuan, an increase of 12%year -on -year, 35 projects with a contract of over 100 million yuan, 11 projects of more than 1 billion yuan, and a total investment of 23.26 billion yuan. Yuan.

At present, Hangzhou Pharmaceutical Port has gathered more than 1,500 biomedical companies, and 7 major pharmaceutical companies such as Merck, Abbott, Johnson & Johnson have settled here, attracting 29 public service platforms including the Institute of Basic Medicine and Cancer Institute of the Chinese Academy of Sciences.

The achievements of the results are inseparable from the integration of the "six chains" of Hangzhou Pharmaceutical Port through the industrial chain, innovation chain, ecological chain, talent chain, financial chain, and service chain. For example, in terms of policy chain, a type of innovative drugs give 40%of R & D investment and up to 48 million yuan in funding support.

At the summit site, Sriom Biological Project, Wenda Pharmaceutical Project, Hangzhou Health and Health Commission Transformation Center Project, Zhejiang University Institute of Biotechnology Project signed a contract and settled in Qiantang, injecting fresh blood into the biomedical industry of Qiantang District.

The opening ceremony also held a signing ceremony for the strategic cooperation cooperation of infrastructure investment business in the Biomedical Industrial Park for Biopharmaceutical Industry Fund. At the same time, Hangzhou Dacian Town's "Provincial Overseas Chinese Innovation and Entrepreneurship Position" was officially awarded, the Zhejiang Biopharmaceutical Industry Research Alliance was established, and the "White Triangle Biomedical Industry White Paper" was released.

In addition, the Hangzhou area of ​​Zhejiang Free Trade Zone officially launched the pilot pilot of the joint supervision mechanism of special items in immigration. It aims to further optimize the management procedures for the entry management procedures of special items and effectively solve the deep problems of the development of enterprises. List company. (Reporter: Hao Shuang, Zhu Sheng)

- END -